Bacopa Monneiri, Attention deficit Hyperactivity Disorder

EFFICACY OF BACOPA MONNEIRI IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN SCHOOL & COLLEGE GOING AGE GROUP : RANDOMISED CONTROLLED TRIAL USING SNAP-IV SCORE - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/065939

Enrollment

100

Registered

2024-04-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F900- Attention-deficit hyperactivity disorder, predominantly inattentive type

Interventions

Intervention1: Bacopa Monneiri Homoeopathic Medicine: Bacopa Monneiri Potency 1 X Route of Administration Oral Dose 1 tablet to times a day Duration 6 month Control Intervention1: Placebo: Homoeopat

Eligibility

Inclusion criteria

Inclusion criteria: Children & young persons of a mixed variety of Attention Deficit Hyperactivity Disorder as per DSM 5 Criteria Children & young persons of WITH ENLISH Literate Parents

Exclusion criteria

Exclusion criteria: Children with any chronic physical or neurological disorder History of drug abuse History of seizure History of Tic disorder History of Tourette syndrome Severely ill in need of hospitalization and patients who are on anti ADHD or psychoactive medications in the previous 2wks

Design outcomes

Primary

Measure	Time frame
Swanson Nolan And Pelham Rating Scale SNAP IV 26 itemsTimepoint: PRESTUDY MIDSTUDY POSTSTUDY	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactDr Swati Makarand Bhagwat

Maharashtra University of Health Sciences Nashik

drsarojsawant212@gmail.com9604656093

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026